While Integra Lifesciences Holdings Corp has overperformed by 3.02%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, IART fell by -40.62%, with highs and lows ranging from $45.42 to $16.81, whereas the simple moving average jumped by 4.44% in the last 200 days.
On December 02, 2024, Morgan Stanley started tracking Integra Lifesciences Holdings Corp (NASDAQ: IART) recommending Underweight. A report published by BTIG Research on October 07, 2024, Upgraded its rating to ‘Neutral’ for IART. Citigroup also Downgraded IART shares as ‘Sell’, setting a target price of $23 on the company’s shares in a report dated July 30, 2024. Wells Fargo May 07, 2024d its ‘Overweight’ rating to ‘Equal Weight’ for IART, as published in its report on May 07, 2024. Citigroup also rated the stock as ‘Neutral’.
Analysis of Integra Lifesciences Holdings Corp (IART)
Further, the quarter-over-quarter decrease in sales is -0.41%, showing a negative trend in the upcoming months.
In order to gain a clear picture of Integra Lifesciences Holdings Corp’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -0.42% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 0.73, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 752.27K can be a very valuable indicator of volatility for IART stock. On a monthly basis, the volatility of the stock is set at 4.01%, whereas on a weekly basis, it is put at 4.69%, with a gain of 14.18% over the past seven days. Furthermore, long-term investors anticipate a median target price of $26.00, showing growth from the present price of $25.60, which can serve as yet another indication of whether IART is worth investing in or should be passed over.
How Do You Analyze Integra Lifesciences Holdings Corp Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 14.31%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 92.79% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
IART shares are owned by institutional investors to the tune of 92.79% at present.
